Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: An open-label phase 1 safety trial

The Lancet Respiratory Medicine

Volumn 2, Issue 2, 2014, Pages 108-122

  Skrahin, Aliaksandr ^a,b   Ahmed, Raija K ^c   Ferrara, Giovanni ^d   Rane, Lalit ^e   Poiret, Thomas ^e   Isaikina, Yanina ^f   Skrahina, Alena ^a   Zumla, Alimuddin ^g,h   Maeurer, Markus J ^e,i  

^a National Research and Practical Centre for Pulmonology and Tuberculosis   (Belarus)

^b BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d UNIVERSITY OF PERUGIA   (Italy)

^e KAROLINSKA INSTITUTE   (Sweden)

^f Haematology and Immunology   (Belarus)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INFUSION PUMPS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REPUBLIC OF BELARUS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84895074569     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70234-0     Document Type: Article

References (88)

1. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 2010, 18:237. WHO.
2. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006, 55:301-305. CDC.
3. Trends in tuberculosis-United States, 2005. MMWR Morb Mortal Wkly Rep 2006, 55:305-308. CDC.
4. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
5. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
6. Gao XF, Yang ZW, Li J Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis 2011, 15:e594-e600.
7. Yamada G, Shijubo N, Shigehara K, Okamura H, Kurimoto M, Abe S Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000, 161:1786-1789.
8. Barnes PF Immunotherapy for tuberculosis: wave of the future or tilting at windmills?. Am J Respir Crit Care Med 2003, 168:142-143.
9. Muthuswamy P, Hu TC, Carasso B, Antonio M, Dandamudi N Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature. Chest 1995, 107:1621-1630.
10. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005, 191:856-865.
11. Spellberg B, Bartlett JG, Gilbert DN The future of antibiotics and resistance. N Engl J Med 2013, 368:299-302.
12. Auletta JJ, Deans RJ, Bartholomew AM Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012, 119:1801-1809.
13. Friedenstein AJ, Chailakhjan RK, Lalykina KS The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3:393-403.
14. Hogan BL, Yingling JM Epithelial/mesenchymal interactions and branching morphogenesis of the lung. Curr Opin Genet Dev 1998, 8:481-486.
15. Sabatini F, Petecchia L, Tavian M, Jodon de Villeroche V, Rossi GA, Brouty-Boye D Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Lab Invest 2005, 85:962-971.
16. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
17. Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012, 302:L829-L837.
18. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012, 18:759-765.
19. Spees JL, Olson SD, Whitney MJ, Prockop DJ Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci USA 2006, 103:1283-1288.
20. Sinclair K, Yerkovich ST, Chambers DC Mesenchymal stem cells and the lung. Respirology 2013, 18:397-411.
21. Forslow U, Blennow O, Leblanc K, et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2012, 89:220-227.
22. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11:150-156.
23. Frenette PS, Pinho S, Lucas D, Scheiermann C Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 2013, 31:285-316.
24. Bang OY, Lee JS, Lee PH, Lee G Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005, 57:874-882.
25. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
26. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
27. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359:563-574.
28. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004, 363:474-481.
29. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 (WHO/HTM/TB/2008.402) WHO, (accessed Nov 14, 2013). http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
30. Kruuner A, Yates MD, Drobniewski FA Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006, 44:811-818.
31. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006, 44:688-692.
32. Ralph AP, Ardian M, Wiguna A, et al. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 2010, 65:863-869.
33. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
34. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932-8937.
35. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012, 7:e47559.
36. Lin Y, Hogan WJ Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hematol 2011, 2011:427863.
37. Magalhaes I, Vudattu NK, Ahmed RK, et al. High content cellular immune profiling reveals differences between rhesus monkeys and men. Immunology 2010, 131:128-140.
38. Magalhaes I, Sizemore DR, Ahmed RK, et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 2008, 3:e3790.
39. Lanzavecchia A, Sallusto F Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000, 290:92-97.
40. Vudattu NK, Magalhaes I, Schmidt M, Seyfert-Margolis V, Maeurer MJ Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer 2007, 121:1512-1519.
41. Svahn A, Linde A, Thorstensson R, Karlen K, Andersson L, Gaines H Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus. J Immunol Methods 2003, 277:17-25.
42. Borgstrom E, Andersen P, Atterfelt F, et al. Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M tuberculosis infection; IP-10 is a promising marker. PLoS One 2012, 7:e43438.
43. Borgstrom E, Andersen P, Andersson L, et al. Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection. J Immunol Methods 2011, 370:55-64.
44. Ahmed RK, Rohava Z, Balaji KN, et al. Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus. BMC Infect Dis 2012, 12:41.
45. Alvarez-Corrales N, Ahmed RK, Rodriguez CA, et al. Differential cellular recognition pattern to M tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras. BMC Infect Dis 2013, 13:125.
46. Lagrelius M, Jones P, Franck K, Gaines H Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytokine 2006, 33:156-165.
47. Sutherland JS, Lalor MK, Black GF, et al. Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. PLoS One 2013, 8:e74080.
48. Bernhard H, Maeurer MJ, Jager E, et al. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-γ. Scand J Immunol 1996, 44:285-292.
49. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995, 181:363-368.
50. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996, 2:1263-1274.
51. Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schafer R Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med 2013, 11:146.
52. Johnson BJ, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997, 78:195-203.
53. Grahmann PR, Braun RK A new protocol for multiple inhalation of IFN-γ successfully treats MDR-TB: a case study. Int J Tuberc Lung Dis 2008, 12:636-644.
54. Muller I, Kordowich S, Holzwarth C, et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444.
55. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005, 23:1357-1366.
56. Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004, 9:747-756.
57. Jung S, Sen A, Rosenberg L, Behie LA Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. Cytotherapy 2010, 12:637-657.
58. Bernardo ME, Avanzini MA, Perotti C, et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007, 211:121-130.
59. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
60. Avanzini MA, Bernardo ME, Cometa AM, et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 2009, 94:1649-1660.
61. Schallmoser K, Bartmann C, Rohde E, et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
62. Grundstrom S, Dohlsten M, Sundstedt A IL-2 unresponsiveness in anergic CD4+ T cells is due to defective signaling through the common gamma-chain of the IL-2 receptor. J Immunol 2000, 164:1175-1184.
63. Omar H, Ahmed R, Rane L, et al. Decreased IL-7 signaling in T cells from patients with PTLD after allogeneic HSCT. J Immunother 2011, 34:390-396.
64. Bazdar DA, Kalinowska M, Sieg SF Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging. J Infect Dis 2009, 199:1019-1028.
65. Osei-Bimpong A, Meek JH, Lewis SM ESR or CRP? A comparison of their clinical utility. Hematology 2007, 12:353-357.
66. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
67. Hanekom WA, Dockrell HM, Ottenhoff TH, et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008, 5:e145.
68. Matthews K, Ntsekhe M, Syed F, et al. HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Eur J Immunol 2012, 42:147-157.
69. Harari A, Rozot V, Enders FB, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011, 17:372-376.
70. Tripathi P, Kurtulus S, Wojciechowski S, et al. STAT5 is critical to maintain effector CD8+ T cell responses. J Immunol 2010, 185:2116-2124.
71. Upadhyay P Tuberculosis vaccine trials. Lancet 2013, 381:2253-2254.
72. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 2012, 205(suppl 2):S301-S315.
73. Smith I Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003, 16:463-496.
74. Lin PL, Flynn JL Understanding latent tuberculosis: a moving target. J Immunol 2010, 185:15-22.
75. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997, 3:678-681.
76. Henter JI, Palmkvist-Kaijser K, Holzgraefe B, Bryceson YT, Palmer K Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010, 376:2116.
77. Seitzer U, Kayser K, Hohn H, et al. Reduced T-cell receptor CD3e-chain protein and sustained CD3e expression at the site of mycobacterial infection. Immunology 2001, 104:269-277.
78. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G Tuberculosis and HIV co-infection. PLoS Pathog 2012, 8:e1002464.
79. Prockop DJ, Oh JY Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012, 20:14-20.
80. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010, 5:e10088.
81. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010, 138:965-972.
82. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007, 179:1855-1863.
83. Zhao F, Zhang YF, Liu YG, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 2008, 40:1700-1705.
84. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003, 100:8407-8411.
85. Meisel R, Brockers S, Heseler K, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011, 25:648-654.
86. Van Linthout S, Savvatis K, Miteva K, et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2011, 32:2168-2178.
87. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010, 182:1047-1057.
88. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010, 28:2229-2238.